Part II: Subsequent entry biologics: Biosame or biodifferent?

MBiotech alumna Eva Furczon and Associate Director Leigh Revers recognized a need for today's generation of pharmacists to become better informed about the history of biologics and to learn how they differ from the more conventional small-molecule drugs that are prevalent in pharmacopeias.

Revers and Furczon wrote a two-part series entitled "An Introduction to Biologics". In Part I: Biologics - What are they and where do they come from?, they sought to define biologics and examine their short history.

In the just released Part II: Subsequent entry biologics: Biosame or biodifferent?, the authors explore the diversity of biologics and discuss the challenges for "follow-on", or generic, versions known as biosimilars.

With the arrival of the first SEB (subsequent entry biologic) Omnitrope® in Canada in 2009, SEBs are here to stay. However, pharmacists faced with choices between first-in-class brand biologic drugs and generics need to be in a position to make informed choices. The authors' aim with this review is to further the general understanding of biologics and to highlight current thinking about why care is needed when evaluating SEBs as potential alternatives in health care.

"An Introduction to Biologics" is a useful review for any healthcare professional or industry representative that wants to learn more about this current topic.